Skip to main content

Halstead Michael's Form 4 filing

Intra-Cellular Therapies, Inc.ITCI · filed Mar 11, 2024

Accession no.
0000950170-24-029581
Filed
Mar 11, 2024
Trade date
Mar 7-11, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.35M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Halstead MichaelCIK 0001521548Officer (EVP and General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 7, 2024Common StockSSaleDisposed−12,912$66.14F2−$853,999.68220Direct
Mar 7, 2024Common StockSSaleDisposed−220$66.81F3−$14,698.20Direct
Mar 10, 2024Common StockMOption exerciseAcquired+7,345–F4–7,345Direct
Mar 11, 2024Common StockSSaleDisposed−6,107$65.82F5−$401,962.741,238Direct
Mar 11, 2024Common StockSSaleDisposed−1,238$66.70F6−$82,574.60Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2024Common StockMOption exerciseDisposed−7,345$0.00$07,345Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.69 to $66.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.7115 to $66.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F4

Restricted stock units convert into common stock on a one-for-one basis.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.31 to $66.302, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)